Attorney's Docket No.: 22578-0005US1 / 079.US2.PCT

Applicant : Semple, et al. Serial No.: 10/535,345 Filed : February 15, 2006 Page : 2 of 19

Amendments to the Claims:

Please cancel claims 29-30 and add new claims 43-64. Further, please amend claims 28, 31, and 41 as follows. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-3. (Canceled)

- 4. (Previously Presented) A compound selected from:
 - 3-(1H-Tetrazol-5-vI)-2.4.5.6-tetrahydro-cyclopentapyrazole:
 - 3-(1H-Tetrazol-5-vI)-2.4-dihydro-cyclopentapyrazole:
 - 3-(1H-Tetrazol-5-vl)-2.6-dihydro-cyclonentapyrazole:
 - 5-Butyl-3-(1H-tetrazol-5-vl)-2.4.5.6-tetrahydro-cyclopentapyrazole:
 - 5-Propvl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
 - 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
 - 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
 - 5-Fluoro-3-(1H-tetrazol-5-vl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
 - 5-Isobutoxy-3-(1H-tetrazol-5-vl)-2.4.5.6-tetrahydro-cyclopentapyrazole;
 - 5-Butoxy-3-(1H-tetrazol-5-vf)-2.4,5,6-tetrahydro-cyclopentapyrazole; and
- 5-Ethoxy-3-(1H-tetrazol-5-vl)-2.4.5.6-tetrahydro-cyclopentapyrazole; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

5-6. (Canceled)

7. (Previously Presented) The compound according to claim 4 that is 3-(1H-Tetrazol-5-vl)-2.4.5.6tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

8-9. (Canceled)

Attorney's Docket No.: 22578-0005US1 / 079.US2.PCT

Applicant : Semple, et al. Serial No.: 10/535,345 : February 15, 2006

Page : 3 of 19

- 10. (Previously Presented) The compound according to claim 4 that is 3-(1H-Tetrazol-5-vl)-2.4dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 11. (Previously Presented) The compound according to claim 4 that is 3-(1H-Tetrazol-5-yl)-2,6dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 12-13. (Canceled)
- The compound according to claim 4 that is 5-Butyl-3-(1H-tetrazol-5-vl)-14. (Previously Presented) 2.4.5.6-tetrahydro-cyclonentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 15-16. (Canceled)
- 17. (Previously Presented) The compound according to claim 4 that is 5-Propyl-3-(1H-tetrazol-5vl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 18. (Previously Presented) The compound according to claim 4 that is 5-Propoxy-3-(1H-tetrazol-5vl)-2.4.5.6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 19. (Previously Presented) The compound according to claim 4 that is 5-Cyclopentyl-3-(1Htetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 20. (Previously Presented) The compound according to claim 4 that is 5-Fluoro-3-(1H-tetrazol-5v1)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

Attorney's Docket No.: 22578-000SUS1 / 079.US2.PCT

Applicant : Semple, et al. Serial No. : 10/535,345 Filed : February 15, 2006

Page : 4 of 19

 (Previously Presented) The compound according to claim 4 that is 5-Isobutoxy-3-(1H-tetrazol-5yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

 (Previously Presented) The compound according to claim 4 that is 5-Butoxy-3-(1H-tetrazol-5yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

23-25. (Canceled)

- (Previously Presented) The compound according to claim 4 that is 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 27. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in combination with a pharmaceutically acceptable carrier.
- 28. (Currently Amended) A method of treatment-of-a metabolic relaxed-disorder [overing trig] verticles in an individual comprising administrating to an individual in need-of-assist result resulting individual at the repetited properties amount of a compound according to claim 4, or a pharmacouttically acceptable sall, solvate or bydrate thereof.

29-30. (Canceled)

31. (Currently Amended) A method of raising HDL lowering free fatty acids in an individual comprising administering to said individual a therapeutically-effective amount of a compound according to claim 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

32-40. (Canceled)

Attorney's Docket No.: 22578-000SUS1 / 079 US2 PCT

Applicant : Semple, et al. Serial No. : 10/535,345 Filed : February 15, 2006

Page : 5 of 19

41. (Currently amended) A method of producing a pharmaceutical composition comprising admixing a compound according to claim 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof, with a pharmaceutically acceptable carrier.

42. (Canceled)

- 43. (New) The method according to claim 28, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof
- 44. (New) The method according to claim 28, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,4dihydro-evelopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- (New) The method according to claim 28, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,6dihydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- (New) The method according to claim 28, wherein said compound is 5-Butyl-3-(IH-tetrazol-5yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- (New) The method according to claim 28, wherein said compound is 5-Propyl-3-{IH-sterazol-5yl-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- (New) The method according to claim 28, wherein said compound is 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- (New) The method according to claim 28, wherein said compound is 5-Cyclopentyl-3-(IHtetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.

Attorney's Docket No.: 22578-0005US1 / 079 US2 PCT

Applicant : Semple, et al. Serial No.: 10/535,345

Filed : February 15, 2006 Page : 6 of 19

- 50. (New) The method according to claim 28, wherein said compound is 5-Fluoro-3-(1H-tetrazol-5vl)-2.4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- The method according to claim 28, wherein said compound is 5-Isobutoxy-3-(1H-51. (New) tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- The method according to claim 28, wherein said compound is 5-Butoxy-3-(1H-52. (New) tetrazol-5-vl)-2.4.5.6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- The method according to claim 28, wherein said compound is 5-Ethoxy-3-(1H-tetrazol-53. (New) 5-vl)-2.4.5.6-tetrahydro-cyclopentanyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- The method according to claim 31, wherein said compound is 3-(1H-Tetrazol-5-vl)-54. (New) 2.4.5.6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- The method according to claim 31, wherein said compound is 3-(1H-Tetrazol-5-vl)-2.4-55. (New) dihydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- 56. (New) The method according to claim 31, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,6dihydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- 57. (New) The method according to claim 31, wherein said compound is 5-Butyl-3-(1H-tetrazol-5vl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof

Attorney's Docket No.: 22578-0005US1 / 079 US2 PCT

Applicant : Semple, et al. Serial No. : 10/535,345 Filed : February 15, 2006

Page : 7 of 19

58. (New) The method according to claim 31, wherein said compound is 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.

- 59. (New) The method according to claim 31, wherein said compound is S-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5-6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- (New) The method according to claim 31, wherein said compound is 5-Cyclopentyl-3-(1Htetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable sail, solvate or hydrate thereof.
- 61. (New) The method according to claim 31, wherein said compound is 5-Fluore-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- 62. (New) The method according to claim 31, wherein said compound is 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- 63. (New) The method according to claim 31, wherein said compound is 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
- 64. (New) The method according to claim 31, wherein said compound is 5-Ethoxy-3-(JH-tetrazol-5-yl)-2-(,5-6-tetrahydro-cyclopentapyrazole, or pharmacoutically acceptable salt, solvate or hydrate thereof.